Dr. Ramkumar Menon, professor and director of the division of basic and translational research in obstetrics and gynecology at The University of Texas Medical Branch in Galveston and one of two principal investigators at the new March of Dimes Texas Collaborative Prematurity Research Center, discusses his career and focus at the PRC: pregnancy-on-a-chip technology that simulates human pregnancy and will be used to validate drugs that may reverse preterm birth.
All content for MODCAST is the property of March of Dimes and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Ramkumar Menon, professor and director of the division of basic and translational research in obstetrics and gynecology at The University of Texas Medical Branch in Galveston and one of two principal investigators at the new March of Dimes Texas Collaborative Prematurity Research Center, discusses his career and focus at the PRC: pregnancy-on-a-chip technology that simulates human pregnancy and will be used to validate drugs that may reverse preterm birth.
Dr. Tony Capra and Dr. Marina Sirota on the Mystery of Spontaneous Preterm Birth
MODCAST
40 minutes
6 months ago
Dr. Tony Capra and Dr. Marina Sirota on the Mystery of Spontaneous Preterm Birth
Dr. Tony Capra and Dr. Marina Sirota, scientists from the March of Dimes Prematurity Research Center (PRC) at the University of California, San Francisco (UCSF), discuss their foundational finding that spontaneous, or unplanned, preterm birth is fundamentally different from indicated preterm birth.
MODCAST
Dr. Ramkumar Menon, professor and director of the division of basic and translational research in obstetrics and gynecology at The University of Texas Medical Branch in Galveston and one of two principal investigators at the new March of Dimes Texas Collaborative Prematurity Research Center, discusses his career and focus at the PRC: pregnancy-on-a-chip technology that simulates human pregnancy and will be used to validate drugs that may reverse preterm birth.
